Navigation Links
Delcath Strengthens Research and Development Team with Key Appointments
Date:10/20/2010

NEW YORK, Oct. 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of William M. Appling as Senior Vice President of Medical Device Research and Development and Queensbury Facility Operations, and Daniel S. Johnston, PhD, to the position of Vice President of Pharmaceutical Research and Development. Mr. Appling and Dr. Johnston will be based in the Company's Queensbury, New York facility and report to Krishna Kandarpa, MD, PhD, Executive Vice President of Research and Development and Delcath's Chief Medical Officer.

"These key appointments now complete our Research & Development senior leadership team, and add significant expertise in medical device and pharmaceutical development to our organization as a whole," said Eamonn P. Hobbs, President and CEO. "Bill brings deep technical and organizational skills to our R&D and Operations teams, and Dan adds strong knowledge of oncology drug development that will be important as we pursue additional indications for our Chemosaturation System. We are pleased to welcome Bill and Dan to Delcath, and look forward to their contributions to successful commercialization of Chemosaturation."

Prior to joining Delcath, Mr. Appling was employed by AngioDynamics, Inc. where he held various management positions of increasing responsibility. Most recently, he served as Senior Vice President of Research and Development responsible for advanced research, process engineering, and managing an intellectual property portfolio of 285 issued patents and patent applications. Mr. Appling has been included as a named inventor on over 31 issued patents, and 30 pending patent applications. Prior to that, he was Manager of Product Development at E-Z-EM, Inc. Previously, Mr. Appling held product development positions at NAMIC, Inc., American Edwards Labs and Sheridan Catheter Corp.

Dr. Johnston
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
2. Delcath to Present at the William Blair Emerging Growth Stock Conference
3. Delcath to Present at the JMP Securities Healthcare Conference
4. Delcath Systems Announces Completion of Common Stock Offering
5. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
6. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
7. Delcath Systems Announces Second Quarter Progress Report Conference Call
8. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
9. Delcaths Eamonn Hobbs to Ring NASDAQ Opening Bell
10. Delcath Systems Provides Update on Corporate Developments
11. Delcath Signs First Partner Agreement in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... , May 6, 2015  IGI Laboratories, Inc. (NYSE-MKT: IG), ... pharmaceutical company, will be presenting today at the Deutsche Bank ... on May 6 th and 7 th at ... Jason Grenfell-Gardner , CEO and President and ... will present today, May 6, 2015, at 3:30 p.m. ET.   ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:5/6/2015)... Is Colorado’s legal cannabis industry the victim of ... will mark the 18-month milestone of its historic experiment ... Colorado’s legal marijuana industry has been successful and has ... some new challenges. , For example, many marijuana retailers ... the wake of last month’s “420” cannabis celebrations. And ...
(Date:5/6/2015)... 2015 Inversion Studios, a full-service ... and Pilates classes, provides personalized individual instruction and ... with its new Pilates Ring magic circle. , ... leaner, stronger, more centered and graceful, Inversion Studios ... venue to healthy fitness through yoga and Pilates. ...
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 vcfo, ... finance, HR, IT and operational support to optimize business ... Consulting CFOs, Jack Lynch and Michael Scheaffer. Both Lynch ... finance and leadership experience. , “We are delighted ... Ellen Wood, vcfo CEO. “Leveraging their background in financial ...
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto ... of China, has successfully demonstrated a handheld real time ... Anitoa’s handheld qPCR is shown to be capable ... including hepatitis B, C, and E. Coli. This qPCR ... sample and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... NAPA, Calif., April 15 Senetek PLC (OTC,Bulletin Board: ... technologies that target the science of healthy aging, announced ... 2007., Revenue for the year ended December 31, ... for the fourth quarter of 2007,were $223,000, compared with ...
... 15 The Joint Center for,Political and Economic ... of health in order to reduce disparities and ... linked to,socioeconomic status," said Ralph B. Everett, the ... determinants, most health,inequities are avoidable," he added., ...
... a new study to evaluate the impact of a ... Presented at the American Association of Cancer Research Annual ... tracking system is key to improving rates of medical ... eliminating racial disparity in treatment. , Women who ...
... many with the autoimmune disease, researchers say , , TUESDAY, April ... the number of attacks in people with multiple sclerosis appears ... The pill was effective in preventing relapses in more than ... years, according to research that was expected to be presented ...
... Council (ACC) supports the rigorous scientific evaluation process,of ... Evaluation of,Risks to Human Reproduction. Following an expert ... NTP Brief on bisphenol A affirms that,there are ... effects of,bisphenol A on human reproduction and development., ...
... their names to ghost-written studies that exaggerated painkiller,s ... Industry documents reveal that pharmaceutical giant Merck & ... Vioxx research published in top medical journals while ... controversial cox-2 painkiller. , The company apparently also ...
Cached Medicine News:Health News:Senetek PLC Reports 2007 Financial Results 2Health News:Senetek PLC Reports 2007 Financial Results 3Health News:Joint Center Sees Social Determinants of Health as Key to Reducing Disparities at Annual Fund-raising Gala 2Health News:Tracking and feedback registry helps reduce disparities in breast cancer care 2Health News:Pill Reduces Relapses in MS Patients 2Health News:Draft National Toxicology Program Report Supports Safety of Bisphenol A 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 3Health News:Key Vioxx Research Was Written by Merck, Documents Allege 4
... of the benefits and functionality of ... additional feature of being able to ... for importing and storage of up ... This additional feature allows for complete ...
Inquire...
Inquire...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Medicine Products: